Completed PHASE1 INTERVENTIONAL 1-arm NCT01583777

Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer

A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Belinostat in Patients With Advanced Cancer

Sponsor: Acrotech Biopharma Inc.

Conditions Advanced Cancer

Interventions Belinostat

Updated 8 times since 2017 Last updated: Dec 31, 2019 Started: Sep 30, 2013 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01583777, this PHASE1 trial focuses on Advanced Cancer and remains completed. Sponsored by Acrotech Biopharma Inc., it has been updated 8 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2022 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acrotech Biopharma Inc.

Data source: Acrotech Biopharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madrid, Spain